PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics (NASDAQ: PTCT) has announced the approval of equity compensation packages for 35 new employees on March 24, 2025. The compensation includes 12,000 non-statutory stock options and 28,220 restricted stock units (RSUs).
The stock options were granted at an exercise price of $57.03 per share, matching PTC's closing price on the grant date. These options have a 10-year term and vest over four years, with 25% vesting after the first year and 6.25% quarterly thereafter. The RSUs also follow a four-year vesting schedule, with 25% vesting annually.
These inducement grants, approved by PTC's Compensation Committee, comply with Nasdaq Listing Rule 5635(c)(4) and are part of the new employees' compensation packages.
PTC Therapeutics (NASDAQ: PTCT) ha annunciato l'approvazione di pacchetti di compenso azionario per 35 nuovi dipendenti il 24 marzo 2025. La compensazione include 12.000 opzioni su azioni non statutarie e 28.220 unità di azioni vincolate (RSU).
Le opzioni su azioni sono state concesse a un prezzo di esercizio di $57.03 per azione, corrispondente al prezzo di chiusura di PTC nella data di concessione. Queste opzioni hanno una durata di 10 anni e maturano in quattro anni, con il 25% che matura dopo il primo anno e il 6,25% trimestralmente successivamente. Anche le RSU seguono un programma di maturazione di quattro anni, con il 25% che matura annualmente.
Questi incentivi, approvati dal Comitato per la Compensazione di PTC, sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) e fanno parte dei pacchetti di compenso dei nuovi dipendenti.
PTC Therapeutics (NASDAQ: PTCT) ha anunciado la aprobación de paquetes de compensación en acciones para 35 nuevos empleados el 24 de marzo de 2025. La compensación incluye 12,000 opciones sobre acciones no estatutarias y 28,220 unidades de acciones restringidas (RSUs).
Las opciones sobre acciones se otorgaron a un precio de ejercicio de $57.03 por acción, coincidiendo con el precio de cierre de PTC en la fecha de concesión. Estas opciones tienen un plazo de 10 años y se consolidan durante cuatro años, con un 25% consolidándose después del primer año y un 6.25% trimestralmente a partir de entonces. Las RSUs también siguen un calendario de consolidación de cuatro años, con un 25% consolidándose anualmente.
Estos incentivos, aprobados por el Comité de Compensación de PTC, cumplen con la Regla de Cotización de Nasdaq 5635(c)(4) y forman parte de los paquetes de compensación de los nuevos empleados.
PTC Therapeutics (NASDAQ: PTCT)는 2025년 3월 24일에 35명의 신규 직원에 대한 주식 보상 패키지 승인을 발표했습니다. 보상에는 12,000개의 비법적 주식 옵션과 28,220개의 제한 주식 단위(RSU)가 포함됩니다.
주식 옵션은 $57.03의 행사가로 부여되었으며, 이는 부여일의 PTC 종가와 일치합니다. 이 옵션은 10년의 기간을 가지며 4년에 걸쳐 분할됩니다. 첫 해 후 25%가 분할되고, 이후 매 분기 6.25%가 분할됩니다. RSU도 4년 분할 일정에 따라 25%가 매년 분할됩니다.
이 유인책은 PTC의 보상 위원회에 의해 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수하며 신규 직원의 보상 패키지의 일부입니다.
PTC Therapeutics (NASDAQ: PTCT) a annoncé l'approbation de paquets de compensation en actions pour 35 nouveaux employés le 24 mars 2025. La compensation comprend 12 000 options d'achat d'actions non statutaires et 28 220 unités d'actions restreintes (RSU).
Les options d'achat d'actions ont été accordées à un prix d'exercice de 57,03 $ par action, correspondant au prix de clôture de PTC à la date de l'octroi. Ces options ont une durée de 10 ans et s'acquièrent sur quatre ans, avec 25 % acquises après la première année et 6,25 % trimestriellement par la suite. Les RSU suivent également un calendrier d'acquisition de quatre ans, avec 25 % acquises annuellement.
Ces incitations, approuvées par le Comité de Rémunération de PTC, sont conformes à la règle de cotation Nasdaq 5635(c)(4) et font partie des paquets de compensation des nouveaux employés.
PTC Therapeutics (NASDAQ: PTCT) hat am 24. März 2025 die Genehmigung von Aktienvergütungspaketen für 35 neue Mitarbeiter bekannt gegeben. Die Vergütung umfasst 12.000 nicht-statutäre Aktienoptionen und 28.220 eingeschränkte Aktieneinheiten (RSUs).
Die Aktienoptionen wurden zu einem Ausübungspreis von $57.03 pro Aktie gewährt, was dem Schlusskurs von PTC am Tag der Gewährung entspricht. Diese Optionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre fällig, wobei 25% nach dem ersten Jahr und danach vierteljährlich 6,25% fällig werden. Die RSUs folgen ebenfalls einem vierjährigen Vesting-Plan, wobei 25% jährlich fällig werden.
Diese Anreizgewährungen, die vom Vergütungsausschuss von PTC genehmigt wurden, entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und sind Teil der Vergütungspakete der neuen Mitarbeiter.
- Employee retention strategy through long-term equity incentives
- Structured vesting schedule promotes long-term commitment
- Potential future dilution of existing shareholders
- Additional share-based compensation expense impact on financial statements
The inducement grants were approved by PTC's Compensation Committee on March 24, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, X, and LinkedIn.
For more information please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302413763.html
SOURCE PTC Therapeutics, Inc.
FAQ
How many shares were granted in PTC Therapeutics' (PTCT) March 2025 inducement grants?
What is the exercise price for PTCT's March 2025 stock option grants?
What is the vesting schedule for PTC Therapeutics' March 2025 stock options?
How do the RSUs vest in PTCT's March 2025 inducement grants?
